Walleye Capital
BCYC

Walleye Capital’s Bicycle Therapeutics BCYC Stock Holding History

Walleye Capital’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$848 Buy
+200
New +$917 ﹤0.01% 4610
2025
Q3 		– Sell
-1,500
Closed -$10.4K – 4501
2025
Q2 		$10.4K Buy
+1,500
New +$11.9K ﹤0.01% 4305

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Walleye Capital's BCYC Position: Q2 2026 in Review

Walleye Capital opened a new position in Bicycle Therapeutics (BCYC) in Q2 2026: 13,000 shares worth $55.1K. The stake represents ﹤0.01% of the portfolio and ranks #4151 among its holdings. This is a return to the name: Walleye Capital previously reported a position in BCYC as recently as Q4 2025.

Walleye Capital first reported a position in BCYC in Q4 2023 and has held it in 4 quarters since. The position peaked at $2.71M in Q4 2023. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Walleye Capital held 13,000 shares of Bicycle Therapeutics worth $55.1K as of Q2 2026.
  • Bicycle Therapeutics was a new Walleye Capital position in Q2 2026.
  • Bicycle Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4151 holding.
  • Walleye Capital first reported a position in Bicycle Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • Walleye Capital's Bicycle Therapeutics position peaked at $2.71M in Q4 2023.
  • 103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.